DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zolinza (Vorinostat) - Summary

 
 



ZOLINZA SUMMARY

ZOLINZA contains vorinostat, an antineoplastic agent, which is described chemically as N- hydroxy- N'- phenyloctanediamide.

ZOLINZA1 is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.

ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for:

  • Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. (1)

See all Zolinza indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Zolinza (Vorinostat)

Optimizing effectiveness of CAR T cell therapy in lymphoma highlighted in special nordic issue
Source: Immune System / Vaccines News From Medical News Today [2015.08.25]
Chimeric antigen receptor (CAR) T cells, which can specifically recognize and target tumor cells, have resulted in complete responses in patients with leukemia, and although equally promising for...

FDA approves Adcetris for high risk Hodgkin Lymphoma patients
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2015.08.20]
Seattle Genetics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of patients with classical Hodgkin lymphoma (HL)...

Topical drug leads to complete remission for some patients with rare skin lymphoma
Source: Dermatology News From Medical News Today [2015.08.07]
Researchers reveal how a topical drug called resiquimod led to total remission for some patients with a cutaneous T cell lymphoma - a rare skin lymphoma.

Topical gel proves safe, effective treatment for patients with skin T cell lymphoma
Source: Dermatology News From Medical News Today [2015.08.07]
Phase 1 trial first to show topical therapy causes systemic immune response, and may eradicate cancerous cells from treated and untreated lesionsResults of a phase one trial show that an...

Hodgkin's Lymphoma Survivors Face Higher Long-Term Heart Risks
Source: MedicineNet Hodgkins Disease Specialty [2015.04.28]
Title: Hodgkin's Lymphoma Survivors Face Higher Long-Term Heart Risks
Category: Health News
Created: 4/27/2015 12:00:00 AM
Last Editorial Review: 4/28/2015 12:00:00 AM

more news >>

Published Studies Related to Zolinza (Vorinostat)

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. [2010.07]
Histone deacetylase inhibitors (HDACi) affect chromatin remodelling and modulate the expression of aberrantly silenced genes. HDACi have single-agent clinical activity in haematological malignancies and have synergistic anti-leukaemia activity when combined with anthracyclines in vitro... The combination of vorinostat and idarubicin is generally tolerable and active in patients with advanced leukaemia and should be studied in the front-line setting.

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. [2010.01.01]
PURPOSE Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by both histone and nonhistone-mediated mechanisms...

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. [2010]
PURPOSE Vorinostat, a histone deacetylase inhibitor, exerts anticancer effects by both histone and nonhistone-mediated mechanisms...

A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. [2009.11.15]
CONCLUSIONS: Administration of a single supratherapeutic dose of the histone deacetylase inhibitor vorinostat is not associated with prolongation of the QTc interval. A dedicated QTc study in advanced cancer patients is a robust means for assessing risk for ventricular repolarization prolongation.

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. [2011.11.12]
Purpose Combining proteasome and histone deacetylase (HDAC) inhibition has been seen to provide synergistic anti-tumor activity, with complementary effects on a number of signaling pathways. The novel bi-cyclic structure of marizomib with its unique proteasome inhibition, toxicology and efficacy profiles, suggested utility in combining it with an HDAC inhibitor such as vorinostat...

more studies >>

Clinical Trials Related to Zolinza (Vorinostat)

Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma [Not yet recruiting]
1. Rationale In mantle cell lymphoma, the conventional chemotherapy achieves only temporary responses with a median duration of remissions only from 1 to 2 years. Therefore, mantle cell lymphoma is known as one of the B-cell lymphomas with poor prognosis. Although the treatment outcome of mantle cell lymphoma has been improved since intensive chemotherapy regimens such as HyperCVAD was used, a substantial number of patients are still frequently relapsed after chemotherapy. After relapse, most of them became refractory to various kinds of salvage treatment. That is why the results of most salvage chemotherapy regimens were disappointing. In addition, mantle cell lymphoma generally occurs in elderly people. Thus, intensive salvage chemotherapy may not be feasible for elderly patients. Therefore, an effective, novel combination treatment is urgently needed in relapsed or refractory mantle cell lymphoma patients. 2. Hypothesis

- Vorinostat will produce synergism with a combination treatment regimen

(Fludarabine, mitoxantrone, dexamethasone, FND) without overlapping toxicity

- Vorinostat maintenance treatment will reduce the relapse rate in patients

ineligible for autologous stem cell transplantation. 3. Purpose A phase II investigation to determin the effectiveness of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphomain patients with relapsed or refractory mantle cell lymphoma.

Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG) [Not yet recruiting]
The goal of this clinical research study is to learn the highest tolerable dose of temsirolimus that can be combined with a stable dose of vorinostat and/or radiation therapy and given to patients with DIPG. The safety of this treatment combination will also be studied.

Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer [Active, not recruiting]
There is scientific rationale for exploring the role of vorinostat, histone deacetylase inhibitor with capecitabine (X) and cisplatin (P), one of standard chemotherapy in patients with advanced gastric cancer. XP is a new standard of care in advanced gastric cancer (AGC) and vorinostat is a novel targeted agent that prevents tumor cell proliferation, survival and angiogenesis through histone deacetylase inhibition.

Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) [Completed]
The purposes of this study are:

- To determine the maximum tolerated dose (MTD) for the combination of oral vorinostat

and bortezomib in participants with advanced multiple myeloma

- To assess the safety and tolerability of this regimen and to document the participant's

clinical status (by anti-tumor activity) for this combination, as determined per standard of care.

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies [Recruiting]
The goal of this clinical research study is to find the highest tolerable dose of the combination of MLN9708 and vorinostat that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied.

more trials >>

Reports of Suspected Zolinza (Vorinostat) Side Effects

Pyrexia (15)Decreased Appetite (12)Dehydration (10)Pneumonitis (9)Pleural Effusion (8)Febrile Neutropenia (8)Sepsis (8)Disease Progression (6)White Blood Cell Count Decreased (6)Renal Failure (6)more >>


Page last updated: 2015-08-25

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015